National Bank of Canada FI Has $61.76 Million Stock Position in Humana Inc. (NYSE:HUM)

National Bank of Canada FI raised its position in Humana Inc. (NYSE:HUM) by 93.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 131,371 shares of the insurance provider’s stock after buying an additional 63,545 shares during the period. National Bank of Canada FI’s holdings in Humana were worth $61,757,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in HUM. Morgan Stanley raised its stake in shares of Humana by 6.2% in the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after acquiring an additional 119,760 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after purchasing an additional 402,559 shares in the last quarter. Northern Trust Corp raised its position in Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after purchasing an additional 64,245 shares during the last quarter. Invesco Ltd. boosted its stake in Humana by 1.4% in the third quarter. Invesco Ltd. now owns 965,488 shares of the insurance provider’s stock worth $469,729,000 after purchasing an additional 13,670 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Humana by 39.3% during the third quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock worth $331,743,000 after purchasing an additional 192,546 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Down 0.1 %

Shares of HUM traded down $0.44 during midday trading on Friday, hitting $320.54. The stock had a trading volume of 1,802,675 shares, compared to its average volume of 1,607,966. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The firm has a market cap of $38.63 billion, a price-to-earnings ratio of 19.96, a price-to-earnings-growth ratio of 1.86 and a beta of 0.49. The company has a 50 day simple moving average of $324.12 and a two-hundred day simple moving average of $387.61. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $541.21.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The firm had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $9.38 EPS. On average, analysts anticipate that Humana Inc. will post 16.18 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Analysts Set New Price Targets

HUM has been the subject of a number of research analyst reports. Wells Fargo & Company cut their price target on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. UBS Group reduced their target price on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Cantor Fitzgerald lowered their price target on shares of Humana from $391.00 to $360.00 and set a “neutral” rating for the company in a report on Thursday, April 25th. Truist Financial reaffirmed a “hold” rating and set a $550.00 price objective on shares of Humana in a report on Friday, January 19th. Finally, TheStreet downgraded Humana from a “b” rating to a “c+” rating in a research report on Monday, January 8th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $424.50.

Insider Activity at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.